A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer

References

Page 1

	Year	Citations
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer Joan H. Schiller, David Harrington, Chandra P. Belani, New England Journal of Medicine	2002	4.9K
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER J Oan H. S Chiller, D Avid H Arrington, C Handra P. B Elani, Median SurvivalMedicineCancer ManagementPharmacologyToreceive Cisplatin	2002	3.7K
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials BMJ	1995	2.9K
Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials Lung Cancer Individual PatientsMedicineMetronomic TherapyRandomised Clinical TrialsClinical Trials	1996	2.5K
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy Frances A. Shepherd, Janet Dancey, Rodryg Ramlau, Journal of Clinical Oncology	2000	2.2K
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens Frank V. Fossella, Russell F. DeVore, Ronald N. Kerr, Journal of Clinical Oncology	2000	1.4K
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria Stephanie Green, Geoffrey R. Weiss Investigational New Drugs OncologyToxicity CriteriaCancer ManagementSouthwest Oncology GroupClinical Endpoint	1992	613
Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Valerie W. Rusch, José Baselga, Carlos Cordon‐Cardo, PubMed Lung InflammationPathologyPrimary NsclcGrowth Factor AlphaCancer Biology	1993	488
A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced-EGFR-expressing, non-small cell lung cancer (NSCLC) R. Perez‐Soler Medical Entomology and Zoology Phase Ii TrialMedicinePharmacologyCancer GrowthPathology	2001	192
Final results from a phase II trial of ZD1839 ("Iressa") for patients with advanced non-small-cell lung cancer (IDEAL 1) M. Fukuoka Medical Entomology and Zoology Final ResultsPhase Ii TrialAdvanced Lung DiseaseMedicineClinical Trials	2002	171

Page 1